Two Children Died in Hidden Chinese Gene-Editing Trials: A Crisis of Transparency and Oversight

Two previously undisclosed child deaths in separate Chinese gene-editing clinical trials have been brought to light by a joint investigation from Science and Retraction Watch . The revelations—one involving a 6-year-old girl who died in March 2025 and another involving a young boy with Duchenne muscular dystrophy who died in August 2025—have sparked a global crisis of confidence in China's regulatory oversight and research ethics . Both trials exploited a regulatory loophole that allowed them to proceed without prior approval from the national drug regulator, and in both cases, the deaths were concealed from the public for months or even over a year .

The First Case: A 6-Year-Old Girl and a World-First Brain Therapy

On March 24, 2025, a 6-year-old girl given the pseudonym "Mei" became the first person in the world to receive brain-directed base-editing therapy . The procedure took place at Xinhua Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, and was led by neuroscientist Zilong Qiu . Mei had Snijders Blok–Campeau syndrome, a rare neurodevelopmental disorder caused by a CHD3 gene mutation. The condition can cause speech delays and intellectual disability but is not life-threatening .

Mei received an infusion of trillions of AAV viruses carrying a base editor into her spinal fluid . She died seven days later, on March 31, 2025 . An internal hospital ethics committee determined the cause of death was thrombotic microangiopathy triggered by the high-dose AAV delivery—a severe immune reaction that caused fever, kidney failure, and fatal clotting .

Months after Mei's death, Qiu's team published a paper describing the preclinical work in Nature . The paper did not disclose that the therapy had been tested in a human patient, nor did it mention her death . It also omitted the fact that Mei's parents had paid $860,000 to fund the preclinical development and treatment .

According to a report in Science, the family has asked the authors to withdraw the paper . Nature subsequently launched its own investigation into the paper .

The Aftermath

Shanghai Jiao Tong University School of Medicine announced on July 26, 2026, that it had formed a special task force to conduct a "comprehensive investigation" . Local authorities fined the hospital approximately $3,600 over oversight and registration failures but did not sanction the lead researcher .

The Second Case: A Boy in a Duchenne Muscular Dystrophy Trial

Separately, a child—reported to be a young boy—died in August 2025 after receiving a high dose of an experimental CRISPR gene-editing therapy for Duchenne muscular dystrophy (DMD) . The therapy, called HG302, was developed by Shanghai-based HuidaGene Therapeutics and delivered systemically via an AAV9 vector . The trial, known as HG302-01, was a first-in-human investigator-initiated trial .

HuidaGene's own investigation, which included lab tests, immunology analysis, pathology, and an autopsy, attributed the death to acute respiratory distress syndrome (ARDS) arising in the context of severe complement and cytokine activation after high-dose AAV administration .

The boy's cause of death is strikingly similar to fatal adverse events seen in other high-dose AAV gene therapy trials for DMD, including one conducted by Pfizer . HuidaGene's CEO, Alvin Luk, had previously acknowledged that other AAV micro-dystrophin trials had observed serious adverse events, including death, at high doses .

A 12-Month Silence

HuidaGene knew by January 2026 that it had sufficient data for peer review, but it did not publicly disclose the death until August 5, 2026—nearly 12 months after it occurred . The disclosure came only after investigative pressure from reporters . The clinical trial registry listing had been quietly updated to "complete" in February 2026 .

Company leaders Alvin Luk (CEO) and TJ Cradick (CTO) had quietly departed in summer 2025, around the time of the death . Cradick, a U.S.-based gene-editing executive, had been at the company for less than a year .

The Regulatory Loophole: China's IIT Pathway

Both trials exploited a regulatory pathway unique to China: the investigator-initiated trial (IIT). Under China's quasi-dual-track regulatory system, hospitals can conduct early-phase gene therapy studies after only a local ethics review—without any approval from the National Medical Products Administration (NMPA), the country's national drug regulator . This "therapeutic track" was designed to accelerate innovation, but critics say it has become a dangerous loophole that bypasses independent pre-trial oversight .

A Nature analysis noted that these trials "are led by physician-investigators and regulated by health authorities, without input from the country's national drug regulator" . The IIT model in China has surged 11-fold from 2015 to 2023, with IITs for cell and gene therapies enrolling over 30,000 participants .

Key Regulatory Gaps Identified

• No mandatory reporting of serious adverse events to a central national authority.
• No requirement for public disclosure of fatalities in academic publications.
• No independent pre-trial review of the risk-benefit balance, especially for non-life-threatening conditions.
• Financial conflicts of interest—such as the parents funding their own child's trial—are not required to be disclosed .

A New Regulation, But Too Late

China's State Council promulgated a new unified regulation (Decree No. 818) in October 2025, effective May 1, 2026, designed to close many of these gaps . The new rules establish a unified governance framework for IITs and require scientific review and ethics committee approval . However, neither of the two fatal trials fell under its scope .

Ethical Criticisms

The cases have drawn sharp condemnation from experts in research ethics.

Shi Jiayou, a law professor at Renmin University of China, stated that subjecting a child with a non-life-threatening condition to known lethal risks violates the principles of minimizing harm and ensuring controllable risk under China's Measures for Ethical Review of Life Science and Medical Research .

Additional ethical failings identified by multiple experts and the Science / Retraction Watch investigation include :

• The informed consent form for Mei's trial allegedly did not list death as a possible risk .
• Preclinical animal studies had already shown severe safety signals, including deaths in non-human primates at similar doses, yet the human trial proceeded .
• The $860,000 payment by Mei's parents created a coercive financial dynamic and a major undisclosed conflict of interest .

Critics argue that the desperation of families seeking cures for rare diseases is being exploited by a system that prioritizes speed and prestige over patient safety .

Consequences and the Future

The immediate consequence has been a crisis of confidence. The revelations threaten to undermine China's ambitious push to become a global leader in gene and cell therapy. Some scientists and industry figures fear Chinese policymakers may now curtail the regulatory flexibility that enabled the rapid expansion of gene therapy trials, potentially slowing innovation .

However, as one industry observer noted on LinkedIn, China's regulatory flexibility has also been a competitive advantage . The new IIT framework under Decree No. 818 may provide a more robust oversight structure, but the legacy of these two undisclosed deaths will likely shape the global debate on how much speed is worth the risk.

The Bottom Line

Two children died in separate Chinese gene-editing trials, and their deaths were concealed. The core takeaway is that regulatory frameworks designed to accelerate the development of life-saving therapies can become dangerously permissive without mandatory, independent oversight and transparent disclosure of adverse events. Safeguards that exist in other major research economies—including independent data monitoring committees, mandatory public registries, and central reporting of fatalities—were not in place for these trials.